BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7868940)

  • 1. Combination treatment of nitrosamine-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist.
    Szepshazi K; Halmos G; Groot K; Schally AV
    Int J Pancreatol; 1994; 16(2-3):141-9. PubMed ID: 7868940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.
    Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
    Cancer Res; 1990 Jun; 50(12):3716-21. PubMed ID: 2160323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters.
    Szepeshazi K; Lapis K; Schally AV
    Int J Cancer; 1991 Sep; 49(2):260-6. PubMed ID: 1679045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J; Halmos G; Szepeshazi K; Schally AV
    Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K; Schally AV; Groot K; Halmos G
    Int J Cancer; 1993 May; 54(2):282-9. PubMed ID: 8387464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR; Radulovic S; Groot K; Schally AV
    Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K; Schally AV; Cai RZ; Radulovic S; Milovanovic S; Szoke B
    Cancer Res; 1991 Nov; 51(21):5980-6. PubMed ID: 1682039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
    Fekete M; Zalatnai A; Schally AV
    Cancer Lett; 1989 May; 45(2):87-91. PubMed ID: 2567204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
    Radulovic S; Comaru-Schally AM; Milovanovic S; Schally AV
    Pancreas; 1993 Jan; 8(1):88-97. PubMed ID: 8093555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane receptors for peptides in experimental and human pancreatic cancers.
    Fekete M; Zalatnai A; Comaru-Schally AM; Schally AV
    Pancreas; 1989; 4(5):521-8. PubMed ID: 2573055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression.
    Szende B; Srkalovic G; Schally AV; Lapis K; Groot K
    Cancer; 1990 May; 65(10):2279-90. PubMed ID: 1971771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.
    Szende B; Zalatnai A; Schally AV
    Proc Natl Acad Sci U S A; 1989 Mar; 86(5):1643-7. PubMed ID: 2564204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
    Jungwirth A; Pinski J; Galvan G; Halmos G; Szepeshazi K; Cai RZ; Groot K; Vadillo-Buenfil M; Schally AV
    Eur J Cancer; 1997 Jun; 33(7):1141-8. PubMed ID: 9376196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules.
    Zalatnai A; Schally AV
    Cancer Res; 1989 Apr; 49(7):1810-5. PubMed ID: 2564312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone.
    Paz-Bouza JI; Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1987 Feb; 84(4):1112-6. PubMed ID: 2881296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
    Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
    Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
    Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs.
    Szepesházi K; Halmos G; Schally AV; Arencibia JM; Groot K; Vadillo-Buenfil M; Rodriguez-Martin E
    J Cancer Res Clin Oncol; 1999; 125(8-9):444-52. PubMed ID: 10480336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responsiveness of the hamster pancreatic cancer to treatment with microcapsules of D-Trp-6-LH-RH and somatostatin analog RC-160. Histological evidence of improvement.
    Zalatnai A; Schally AV
    Int J Pancreatol; 1989 Mar; 4(2):149-60. PubMed ID: 2566638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
    Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.